Related Experiment Videos
Theranostic Nanomedicine for Malignant Gliomas
Michele d'Angelo1, Vanessa Castelli1, Elisabetta Benedetti1
1Department of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy.
Abstract:
Brain tumors mainly originate from glial cells and are classified as gliomas. Malignant gliomas represent an incurable disease; indeed, after surgery and chemotherapy, recurrence appears within a few months, and mortality has remained high in the last decades. This is mainly due to the heterogeneity of malignant gliomas, indicating that a single therapy is not effective for all patients. In this regard, the advent of theranostic nanomedicine, a combination of imaging and therapeutic agents, represents a strategic tool for the management of malignant brain tumors, allowing for the detection of therapies that are specific to the single patient and avoiding overdosing the non-responders. Here, recent theranostic nanomedicine approaches for glioma therapy are described.
Insights
Theranostic nanomedicine offers a personalized approach to treating malignant brain tumors like gliomas. This strategy combines imaging and therapy for targeted treatment, improving patient outcomes for this incurable disease.
Area of Science:
- Neuro-oncology
- Nanomedicine
- Molecular imaging
Background:
- Malignant gliomas are aggressive brain tumors with high mortality rates.
- Tumor heterogeneity limits the effectiveness of single therapeutic approaches.
- Current treatments like surgery and chemotherapy often result in rapid recurrence.
Purpose of the Study:
- To review recent advancements in theranostic nanomedicine for glioma treatment.
- To highlight the potential of personalized nanomedicine in managing malignant brain tumors.
- To discuss strategies for overcoming treatment resistance in gliomas.
Main Methods:
- Literature review of theranostic nanomedicine applications in glioma research.
- Analysis of nanomedicine-based approaches combining diagnostic and therapeutic modalities.
- Focus on strategies addressing tumor heterogeneity and enabling personalized treatment.
Main Results:
- Theranostic nanomedicine enables simultaneous imaging and targeted drug delivery for gliomas.
- Personalized theranostic strategies can improve treatment efficacy by accounting for individual tumor characteristics.
- Nanomedicine offers potential for early detection of treatment response and avoidance of ineffective therapies.
Conclusions:
- Theranostic nanomedicine is a promising strategy for improving outcomes in malignant glioma patients.
- Personalized theranostic approaches are crucial for managing heterogeneous brain tumors.
- Further research into nanomedicine holds potential for developing more effective glioma therapies.